Get the Stockscreener App
1.58
0.64%
0.01
After Hours:
1.53
-0.05
-3.16%
Pliant Therapeutics Inc stock is traded at $1.58, with a volume of 686.08K.
It is up +0.64% in the last 24 hours and up +26.40% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.57
Open:
$1.625
24h Volume:
686.08K
Relative Volume:
0.61
Market Cap:
$96.99M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5113
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+17.91%
1M Performance:
+26.40%
6M Performance:
-85.82%
1Y Performance:
-87.72%
1-Day Range:
$1.57
$1.64
1-Week Range:
$1.33
$1.64
52-Week Range:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.58 | 96.38M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
What drives Pliant Therapeutics Inc. stock priceAccelerated wealth expansion - Autocar Professional
Is Pliant Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
What analysts say about Pliant Therapeutics Inc. stockConsistently profitable trades - Autocar Professional
Pliant Therapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - jammulinksnews.com
Is Pliant Therapeutics Inc. stock a growth or value playHigh Return Potential - Newser
What makes Pliant Therapeutics Inc. stock price move sharplyDefensive Stock Picks with Upside - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
How Pliant Therapeutics Inc. stock performs during market volatilityTrade Ready Signal - Newser
Why Pliant Therapeutics Inc. stock attracts strong analyst attentionLow Risk ROI Maximization - Newser
Pliant Therapeutics Inc (PLRX) Stock: Navigating a Year of Volatility - investchronicle.com
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN) - The Globe and Mail
Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from Russell 2500 Index - MarketScreener
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - The Manila Times
Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock News - GuruFocus
Pliant Therapeutics Provides Update on BEACON-IPF - GlobeNewswire
Pliant Therapeutics Provides Update on BEACON-IPF | PLRX Stock N - GuruFocus
Pliant Therapeutics Inc’s (PLRX) Stock Is Harder To Predict Than You Think - Stocksregister
Pliant Therapeutics amends corporate bylaws, holds stockholder vote By Investing.com - Investing.com Nigeria
Pliant Therapeutics amends corporate bylaws, holds stockholder vote - Investing.com
Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada
Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus
Pliant Therapeutics presents new fibrosis treatment data - Investing.com
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire
How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks
Another Bay Area biotech company announces layoffs - MSN
Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - The Manila Times
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):